Ashish Srinivasan MD PhD

185 posts

Ashish Srinivasan MD PhD banner
Ashish Srinivasan MD PhD

Ashish Srinivasan MD PhD

@Gastro_Ash

Gastroenterologist 🇦🇺 | #IBD Researcher | #MedEd Alum: Oxford, UK #IBD | Erlangen, Germany #IUS Father | Foodie | sports Fan | Imaging Enthusiast

Melbourne, Australia Katılım Mart 2020
215 Takip Edilen239 Takipçiler
Ashish Srinivasan MD PhD
Ashish Srinivasan MD PhD@Gastro_Ash·
Does access to #IUS change use of #MRE & #colonoscopy in #IBD? 🤔 We asked clinicians at referral (>400): were they choosing #IUS instead of #MRE or #colonoscopy? 🔄 184 MREs 130 colons avoided 💰 AUD $360K (USD $232K) saved 🌱 11,907 kgCO₂e reduced ➡️ bit.ly/3Ok3ake
Frontline Gastro@FrontGastro_BMJ

🤔 How has access to intestinal ultrasound (IUS) reduced 💴 costs and ⛽ carbon emission during diagnostic decision making for IBD by avoidance of MRE and colonoscopy❓ ✅ Come check out this interesting 📡 2️⃣-year prospective study conducted in 🇦🇺 Australia by @Gastro_Ash Darren Wong Riva Porwal @dr_schulberg Ronald Ma Josephine A Grace Peter De Cruz ➡️ this study demonstrates IUS is a cost-effective and sustainable disease monitoring strategy in IBD ➡️ bit.ly/3Ok3ake ↪️ Thank you to our authors❗ Study 🔦 highlights 💠 IUS replaced 184 MREs 💠 IUS replaced 130 colonoscopies 💠 Cost savings of AUD (Australian dollar) $360 822 (USD $231 893) 💠 Reduction in carbon emissions of 11 907 kgCO₂e over 24 months @PhilSmithIsBack @OTavabie @dr_aditi_kumar @TrevorTabone @eathar_s @IrenePerezMD @KGananandan @zare_benjamin @medicalreg @dtleiberman @BSGtrainees #GITwitter

English
0
1
3
492
Ashish Srinivasan MD PhD
Ashish Srinivasan MD PhD@Gastro_Ash·
To complement our recent study on #biologic safety in #IBD post–#liver #transplant, here’s our JAK inhibitor case series 👥 8 patients: 4 TOF, 1 UPA, 3 switched TOF→UPA ❌ No serious infections ⏳ 17-month median follow-up JCC 2024 📄 doi.org/10.1093/ecco-j…
Ashish Srinivasan MD PhD@Gastro_Ash

📌Biologic safety in #IBD post liver transplant - what’s safest? 💊Gut-specific (VDZ) v systemic (aTNF, UST) agents = similar infectious events ⚠️ Steroid co-therapy = ⬆️ severe infections Out in AP&T 🔗doi.org/10.1111/apt.70… 👏Congrats #SimoneChin! #GITwitter #livertwitter

English
0
2
12
982
Ashish Srinivasan MD PhD retweetledi
roypounder.apt
roypounder.apt@APandT·
Read 'open access' via bit.ly/3GBA5gz "Systemic Biologics Have Similar Safety to Vedolizumab in Inflammatory Bowel Disease Patients Following Liver Transplantation"
roypounder.apt tweet media
English
1
8
16
3.6K
Ashish Srinivasan MD PhD
Ashish Srinivasan MD PhD@Gastro_Ash·
One of the memorable highlights of my radiology sabbatical with @drgauraang in the UK — receiving an ID badge with the title “Honorary Radiologist.” 😄 Appreciated the chance to observe and learn about MRI in IBD #GITwitter #MRI
Ashish Srinivasan MD PhD tweet media
English
0
0
8
268
Ashish Srinivasan MD PhD
Ashish Srinivasan MD PhD@Gastro_Ash·
Tremendous learning experience at my first abdominal radiology conference #ESGAR2025 in Amsterdam - some incredible imaging research in the #IBD space!
English
0
1
7
386
Ashish Srinivasan MD PhD
Ashish Srinivasan MD PhD@Gastro_Ash·
Thanks @rupertleong and the #IBD team at Concord, Sydney for hosting me during my sabbatical - packed in IBD clinics, MDM, IUS, endoscopy! Incredible learning experience - highly encourage everyone to consider spending time at neighboring IBD services -same, same but different!
Ashish Srinivasan MD PhD tweet mediaAshish Srinivasan MD PhD tweet mediaAshish Srinivasan MD PhD tweet media
English
0
0
8
441
Ashish Srinivasan MD PhD retweetledi
John Ding MD PhD
John Ding MD PhD@IBD_JohnD·
Our article on protocolising care through medical and surgical treatment for fistulising Crohn's disease demonstrates that targeting different stages of disease is important➡️⬆️radiologic healing in 25%. Thanks to patients and our team. academic.oup.com/ecco-jcc/advan… @ANZIBDC
English
0
5
28
1.3K
Ashish Srinivasan MD PhD
Ashish Srinivasan MD PhD@Gastro_Ash·
Thanks for shining a spotlight on this important aspect of placebo-controlled drug clinical trials in #IBD. Here’s to hoping for more active comparator trials moving forward. 🤞🏽
DrShahidaDin@ShahidaDin1

Several stakeholders have advocated for minimising placebo controlled RCTs. We analysed the harms [Adverse Events,[AEs]] associated with placebo in inflammatory bowel diseases (IBD) RCTs. @alex_ford12399 @Bealoquebea @Jonathansegal85 @JonnyBlackwell @DrCJBlack @GastroRes_Leeds

English
0
2
5
610
Ashish Srinivasan MD PhD retweetledi
Gastroenterology Network of Intestinal Ultrasound
Great opening session at AGW with live demos and talks on using intestinal ultrasound in IBD and functional gut disorders. Thanks to all our speakers and those doing the live scans!
Gastroenterology Network of Intestinal Ultrasound tweet mediaGastroenterology Network of Intestinal Ultrasound tweet mediaGastroenterology Network of Intestinal Ultrasound tweet mediaGastroenterology Network of Intestinal Ultrasound tweet media
English
0
3
11
406
Ashish Srinivasan MD PhD
Ashish Srinivasan MD PhD@Gastro_Ash·
What great night and kick off #AGW2024! Well done to the #YoungGESA team!
Dr Yoon-Kyo An@DrYoonAn

🌟 Tonight, #YoungGESA truly lit up the night—literally and figuratively! ✨ In our biggest event yet, the rooftop bar was packed with mentors and mentees, all sharing their light to guide each other through the journey. 💡 Remember, no matter where you are in your career, you have something to offer. Let's keep shining brighter together! #MentorshipMatters #AGW2024 @AGWmeeting

English
0
0
4
251
Ashish Srinivasan MD PhD retweetledi
JAMA
JAMA@JAMA_current·
Narrative review explores how to manage use of DOACs—apixaban, rivaroxaban, edoxaban, and dabigatran—in patients undergoing surgical and nonsurgical procedures to decrease risks of bleeding and thromboembolism. ja.ma/3AXfhwV
JAMA tweet media
English
0
154
426
72.2K
Ashish Srinivasan MD PhD
Ashish Srinivasan MD PhD@Gastro_Ash·
@sciqst @BioDrugsJournal Thanks for your interest. Agree that a personalized approach to IFX dosing makes sense. Challenge remains that we don’t know what post-intensification IFX trough levels to target - and whether achieving these levels modify outcomes. But I’m sure we will get there with time.. :)
English
0
0
1
24
Raffaele Di Giacomo, PhD
Raffaele Di Giacomo, PhD@sciqst·
The exploration of post-intensification infliximab trough levels for guiding dose intensification in IBD is fascinating. Personalized medicine approaches like this, which tailor treatments based on specific biomarkers, can significantly improve patient outcomes by tweaking therapy according to individual response. Have you come across any real-world data supporting these PK simulation findings? How does this approach compare to traditional fixed dosing strategies in terms of efficacy and safety? For those interested in more in-depth biomedical discussions and reviews, check out sciqst.com, a comprehensive platform for biomedical queries. #Medicine #IBD #Pharmacokinetics
English
1
0
1
32